Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Abstract Background Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug,...

Full description

Bibliographic Details
Main Authors: Luca Bertamini, Jacopo Nanni, Giovanni Marconi, Mariachiara Abbenante, Valentina Robustelli, Francesco Bacci, Antonella Matti, Stefania Paolini, Chiara Sartor, Silvia Lo Monaco, Maria Chiara Fontana, Stefano De Polo, Michele Cavo, Antonio Curti, Giovanni Martinelli, Cristina Papayannidis
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Cancer
Subjects:
Inotuzumab ozogamicin
Extramedullary
Acute lymphoblastic leukemia
PET-CT scan
Online Access:http://link.springer.com/article/10.1186/s12885-018-5026-x

Internet

http://link.springer.com/article/10.1186/s12885-018-5026-x

Similar Items